In the NEW era of universal adult hepatitis B vaccination1,*
Protecting your adult Patients Can Be As
Heplisav-B is the first and only adult hepatitis B vaccine that provides series completion with just 2 doses in 1 month1-3
HEPLISAV-B NDC#: 43528-0003-05
THE CDC RECOMMENDS UNIVERSAL HEPATITIS B VACCINATION FOR ALL ADULTS AGED 19-591,*
Second to influenza, hepatitis B is projected to have the highest number of eligible patients to vaccinate—the role of pharmacies is critical for helping protect more adult patients against hepatitis B1,4,†
How many adults are eligible for vaccination in 2022?4,†
![Approximately 133 million adults are eligible for hepatitis B vaccination[3,†]](/_nuxt/img/eligible_adult_vaccinations_mobile.ce795c2.png "Number of Adults Eligible for Vaccination in 2022 Graphic")
![Approximately 133 million adults are eligible for hepatitis B vaccination[3,†]](/_nuxt/img/eligible_adult_vaccinations.d909a71.png "Number of Adults Eligible for Vaccination in 2022 Graphic")
See the CDC recommendation for hepatitis B vaccination
Read Full articleThe CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.1
Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccination calculated using US census data published in 2018, CDC coverage data, and risk factor analyses.4
3-dose vaccines can potentially create:
- Additional workflow interruptions
- Time-consuming callbacks & follow-ups
- Scheduling challenges
- Lower rate of series completion
![In a study, approximately 75% of adults aged 19+ did not receive all 3 doses of hepatitis B vaccines[5]](/_nuxt/img/75_percent.e8120d0.png "Low Hepatitis B Vaccine Series Completion for Adults Graphic")
IN A STUDY of adults aged 19+ did not receive all 3 doses5
VACCINES WITH FEWER DOSES CAN BENEFIT PHARMACIES AND PATIENTS6,7
2-dose HEPLISAV-B makes completing the vaccine series faster and more efficient2,8
![HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8]](/_nuxt/img/HEPLISAV-B_series_completion_pharmacists_mobile.4d62d99.png "HEPLISAV-B 2-dose 1-month vs Engerix-B Mobile Graphic")
![HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8]](/_nuxt/img/HEPLISAV-B_series_completion_pharmacists.8ab5c18.png "HEPLISAV-B 2-dose 1-month vs Engerix-B Graphic")
![HEPLISAV-B is an easier option to protect patients and streamline workflows[2,6-8]](/_nuxt/img/2_dose_HEPLISAV-B_mobile.d829d2e.png "HEPLISAV-B Efficient Series Completion Benefits for Pharmacies Mobile Graphic")
![HEPLISAV-B is an easier option to protect patients and streamline workflows[2,6-8]](/_nuxt/img/2_dose_HEPLISAV-B.0888abe.png "HEPLISAV-B Efficient Series Completion Benefits for Pharmacies Graphic")
Don’t delay the switch
EXPLORE INTERCHANGEABILITY![In a recent survey,* most adults preferred a 2-dose, 1-month hepatitis B vaccine over a 3-dose, 6-month vaccine[4]](/_nuxt/img/2_dose_1_month_mobile.ee1b7bb.png "HEPLISAV-B 2-dose 1-month Patient Preference Mobile Graphic")
![In a recent survey,* most adults preferred a 2-dose, 1-month hepatitis B vaccine over a 3-dose, 6-month vaccine[4]](/_nuxt/img/2_dose_1_month.da5bfab.png "HEPLISAV-B 2-dose 1-month Patient Preference Graphic")
![In a recent survey,* most adults preferred a 2-dose, 1-month hepatitis B vaccine over a 3-dose, 6-month vaccine[9]](/_nuxt/img/2x_more_completion_pharmacists_mobile.7a0fd3f.png "HEPLISAV-B 2-dose 1-month Patient Preference Graphic")
![In a recent survey,* most adults preferred a 2-dose, 1-month hepatitis B vaccine over a 3-dose, 6-month vaccine[9]](/_nuxt/img/2x_more_completion_pharmacists.a805ec9.png "HEPLISAV-B 2-dose 1-month Patient Preference Graphic")
In a survey of 1002 adults in the United States who use a pharmacy and are likely to receive a vaccination at a pharmacy, 71.26% (n=714) preferred 2 doses over 1 month, 19.26% (n=193) had no preference, and 9.48% (n=95) preferred 3 doses over 6 months.4
HEPLISAV-B NDC#: 43528-0003-05
EFFICIENT HEPLISAV-B ACCESS HEPLISAV-B NDC#: 43528-0003-05
Coverage parity with other adult hepatitis B vaccines and available to order through distributors
Give your pharmacy the benefits of 2-dose HEPLISAV-B2,6-9
Looking for more information on HEPLISAV-B?
Get ResourcesINDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
References: 1. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed April 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 2. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 3. Haber P, Schillie S. Hepatitis B. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:143-164. 4. Data on file. Dynavax Technologies Corporation; 2022. 5. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi:10.15585/mmwr.ss6611a1 6. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 7. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD. 8. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018. 9. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577
INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.